{"id":903501,"date":"2026-06-30T17:06:18","date_gmt":"2026-06-30T17:06:18","guid":{"rendered":"https:\/\/www.europesays.com\/us\/903501\/"},"modified":"2026-06-30T17:06:18","modified_gmt":"2026-06-30T17:06:18","slug":"canada-approves-generic-version-of-wegovy-for-weight-loss","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/903501\/","title":{"rendered":"Canada approves generic version of Wegovy for weight loss"},"content":{"rendered":"

<\/a> FILE – A dosage of Wegovy, March 1, 2024 in Front Royal, Va. (AP Photo\/Amanda Andrade-Rhoades, File) – The Canadian Press <\/p>\n

OTTAWA \u2014 Health Canada has approved a generic version of Wegovy, a semaglutide drug that’s prescribed to help people lose weight. <\/p>\n

The weekly injection is known as Svemia from the Canadian company Apotex and is pharmaceutically equivalent to weight-loss medication Wegovy from Denmark’s Novo Nordisk. <\/p>\n

Health Canada says Svemia can be prescribed to people 12 years of age and over, as a supplement to a reduced-calorie diet and increased physical activity for weight management. <\/p>\n

It’s the third generic semaglutide medication approved by the department, though the first two were authorized for the treatment of Type 2 diabetes in adults. <\/p>\n

Generic versions of Novo Nordisk’s Ozempic by India-based Dr. Reddy’s Laboratories and Apotex were approved earlier this year. <\/p>\n

Health Canada says it’s reviewing six other submissions for generic semaglutide from different companies and expects to make more decisions in the coming weeks and months. <\/p>\n

“The availability of generic drugs is expected to have a positive impact in Canada, including potential cost savings for patients and the health-care system,” the federal agency said in a news release Monday. <\/p>\n

This report by The Canadian Press was first published June 29, 2026. <\/p>\n

The Canadian Press <\/p>\n","protected":false},"excerpt":{"rendered":"FILE – A dosage of Wegovy, March 1, 2024 in Front Royal, Va. (AP Photo\/Amanda Andrade-Rhoades, File) –…\n","protected":false},"author":3,"featured_media":903502,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[34],"tags":[43907,205624,210,92091,1060,9412,95312,67,132,68,2402,26011],"class_list":["post-903501","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-apotex","tag-generic-version","tag-health","tag-health-canada","tag-medication","tag-novo-nordisk","tag-the-canadian-press","tag-united-states","tag-unitedstates","tag-us","tag-wegovy","tag-weight-management"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116840155811251089","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/903501","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=903501"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/903501\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/903502"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=903501"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=903501"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=903501"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}